Digilife Technologies Ltd. (BAI)

Overview

BenevolentAI S.A. is a pioneering force in the realm of artificial intelligence-driven drug discovery and development. Established in 2013 with its headquarters in London, United Kingdom, the company has positioned itself at the forefront of combining AI technologies and scientific research to revolutionize the pharmaceutical industry. Through its proprietary Benevolent platform, it embarks on uncovering and crafting novel therapeutic solutions aimed at tackling complex diseases. The company does not operate in isolation; it has entered into strategic collaborations with pharmaceutical giants like AstraZeneca and Merck. These partnerships are instrumental in deepening the understanding of intricate disease mechanisms and identifying new therapeutic targets, thereby accelerating the pace at which medical innovations reach patients in need.

Products and Services

• BEN-8744

  An oral phosphodiesterase 10 (PDE10) inhibitor currently in phase 1 clinical studies, BEN-8744 is a promising candidate for the treatment of Ulcerative Colitis. This innovative drug aims to offer new treatment avenues for patients suffering from this chronic and debilitating inflammatory bowel disease.

• BEN-28010

  Embarking on a mission to tackle one of the most aggressive brain tumors, BEN-28010 is an oral brain penetrant CHK1 inhibitor under preclinical study for Glioblastoma Multiforme. Its development underlines BenevolentAI's commitment to addressing unmet medical needs in oncology.

• BEN-34712

  With a focus on neurodegenerative diseases, BEN-34712 emerges as a preclinical candidate for ALS (Amyotrophic Lateral Sclerosis), also known as Lou Gehrig’s disease. This effort signifies a crucial step towards finding viable treatments for this devastating condition.

• Fibrosis and Parkinson's Disease Candidates

  BenevolentAI is also engaging in the development of various candidates aimed at treating fibrosis and Parkinson's disease. These endeavors highlight the company's versatile approach to drug discovery, leveraging its AI platform to unearth treatments for a spectrum of complex diseases.